|
EP2570133B1
(en)
|
2005-11-07 |
2016-03-23 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
SG177953A1
(en)
|
2007-01-05 |
2012-02-28 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
|
BRPI0807728A2
(pt)
|
2007-02-15 |
2012-04-17 |
Univ Indiana Res & Tech Corp |
co-agonistas de receptor glucagon/glp-1
|
|
WO2009058734A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
|
US8981047B2
(en)
|
2007-10-30 |
2015-03-17 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
|
HUE028072T2
(en)
|
2008-06-17 |
2016-11-28 |
Univ Indiana Res & Tech Corp |
GIP-based agonists for the treatment of metabolic disease and obesity
|
|
EA019203B9
(ru)
|
2008-06-17 |
2014-03-31 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты глюкагонового рецептора/glp-1-рецептора
|
|
TWI541023B
(zh)
|
2008-06-17 |
2016-07-11 |
印第安納大學科技研究公司 |
在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
|
|
CA2747499A1
(en)
|
2008-12-19 |
2010-06-24 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
RU2012101274A
(ru)
|
2009-06-16 |
2013-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Соединения глюкагона, активные в отношении рецептора gip
|
|
KR101809024B1
(ko)
|
2009-07-13 |
2017-12-14 |
질랜드 파마 에이/에스 |
아실화 글루카곤 유사체
|
|
EP2512503A4
(en)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
|
|
AR079345A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
RU2012136450A
(ru)
|
2010-01-27 |
2014-03-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
|
|
CN103003300B
(zh)
|
2010-04-27 |
2017-06-09 |
西兰制药公司 |
Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
|
|
EP2568993A4
(en)
|
2010-05-13 |
2014-02-19 |
Univ Indiana Res & Tech Corp |
GLUCAGON SUPERFAMILY PEPTIDES WITH G-PROTEIN-COUPLED RECEPTOR ACTIVITY
|
|
RU2604067C2
(ru)
|
2010-05-13 |
2016-12-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов
|
|
RU2580317C2
(ru)
|
2010-06-24 |
2016-04-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
|
|
MX2013006304A
(es)
|
2010-12-22 |
2013-07-02 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que exhiben actividad del receptor gip.
|
|
WO2012150503A2
(en)
*
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
EP2707713A2
(en)
*
|
2011-05-10 |
2014-03-19 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
PE20140765A1
(es)
*
|
2011-06-10 |
2014-06-14 |
Hanmi Science Co Ltd |
Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
|
|
MX381780B
(es)
*
|
2011-06-17 |
2025-03-13 |
Hanmi Science Co Ltd |
Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo.
|
|
MX347703B
(es)
|
2011-06-22 |
2017-05-09 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1.
|
|
US8729017B2
(en)
|
2011-06-22 |
2014-05-20 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
WO2013004983A1
(en)
|
2011-07-04 |
2013-01-10 |
Imperial Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
|
WO2013064669A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
|
KR20140097151A
(ko)
*
|
2011-11-17 |
2014-08-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
|
|
CA2875743A1
(en)
*
|
2012-06-14 |
2013-12-19 |
Sanofi |
Exendin-4 peptide analogues
|
|
WO2013192129A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
|
UA117103C2
(uk)
|
2012-07-23 |
2018-06-25 |
Зіленд Фарма А/С |
Сполука, яка має активність агоніста глюкагону
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
AR092873A1
(es)
|
2012-09-26 |
2015-05-06 |
Cadila Healthcare Ltd |
Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
SG10201602801YA
(en)
|
2012-11-06 |
2016-05-30 |
Hanmi Pharm Ind Co Ltd |
Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
|
|
JP2016503046A
(ja)
*
|
2012-12-19 |
2016-02-01 |
ノヴォ ノルディスク アー／エス |
コレステロール流出活性を有する新規ｇｌｐ−１受容体アゴニスト
|
|
WO2014096145A1
(en)
|
2012-12-21 |
2014-06-26 |
Sanofi |
Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
|
|
HK1219477A1
(zh)
|
2013-03-21 |
2017-04-07 |
Sanofi-Aventis Deutschland Gmbh |
合成含有乙内酰脲的肽产物
|
|
EP2976325B1
(en)
|
2013-03-21 |
2017-03-01 |
Sanofi-Aventis Deutschland GmbH |
Synthesis of cyclic imide containing peptide products
|
|
AR095986A1
(es)
|
2013-04-03 |
2015-11-25 |
Sanofi Sa |
Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
|
|
KR102302634B1
(ko)
*
|
2013-09-13 |
2021-09-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제 및 이의 조성물
|
|
TWI666220B
(zh)
|
2013-10-17 |
2019-07-21 |
丹麥商西蘭製藥公司 |
醯化升糖素類似物
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
CN105849122B
(zh)
|
2013-11-06 |
2021-04-30 |
西兰制药公司 |
Gip-glp-1双重激动剂化合物及方法
|
|
KR102310392B1
(ko)
|
2013-11-06 |
2021-10-13 |
질랜드 파마 에이/에스 |
글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
|
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／升糖素受體促效劑
|
|
WO2015086731A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
AU2014364589B2
(en)
|
2013-12-18 |
2020-02-27 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
EP3107560A1
(en)
*
|
2014-02-18 |
2016-12-28 |
Novo Nordisk A/S |
Stable glucagon analogues and use for treatment of hypoglycaemia
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
TWI802396B
(zh)
|
2014-09-16 |
2023-05-11 |
南韓商韓美藥品股份有限公司 |
長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
|
|
CN106519015B
(zh)
*
|
2014-09-23 |
2020-04-17 |
深圳市图微安创科技开发有限公司 |
胃泌酸调节素类似物
|
|
WO2016065090A1
(en)
|
2014-10-24 |
2016-04-28 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and glp-1 receptors
|
|
MX381640B
(es)
|
2014-10-29 |
2025-03-04 |
Zealand Pharma As |
Metodos y compuestos agonistas de gip.
|
|
KR102418477B1
(ko)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
글루카곤 유도체
|
|
EP3241841A4
(en)
*
|
2014-12-30 |
2018-10-17 |
Hanmi Pharm. Co., Ltd. |
Glucagon derivative having improved stability
|
|
CA2980978A1
(en)
|
2015-04-16 |
2016-10-20 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
WO2016198628A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
|
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|
|
AU2016287209B2
(en)
*
|
2015-06-30 |
2023-03-02 |
Hanmi Pharm. Co., Ltd. |
Glucagon derivative and a composition comprising a long acting conjugate of the same
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
WO2017062334A1
(en)
|
2015-10-05 |
2017-04-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
|
EP3359194A4
(en)
|
2015-10-06 |
2019-04-24 |
Merck Sharp & Dohme Corp. |
ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
|
|
WO2017074798A2
(en)
*
|
2015-10-27 |
2017-05-04 |
Merck Sharp & Dohme Corp. |
Long-acting co-agonists of the glucagon and glp-1 receptors
|
|
WO2017100107A2
(en)
*
|
2015-12-09 |
2017-06-15 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and glp-1 receptors
|
|
BR112018013530A2
(pt)
|
2015-12-31 |
2018-12-04 |
Hanmi Pharm. Co., Ltd. |
?peptídeo isolado, polinucleotídeo e composição farmacêutica?
|
|
EP3407916B1
(en)
|
2016-01-29 |
2023-12-20 |
Merck Sharp & Dohme LLC |
Phosphonate linkers and their use to facilitate cellular retention of compounds
|
|
KR102005457B1
(ko)
|
2016-06-29 |
2019-07-30 |
한미약품 주식회사 |
글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
|
|
TW201832783A
(zh)
|
2016-12-02 |
2018-09-16 |
法商賽諾菲公司 |
包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
|
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
|
CN108299553B
(zh)
*
|
2017-01-13 |
2021-07-16 |
博瑞生物医药（苏州）股份有限公司 |
胃泌酸调节素修饰物
|
|
CN106986924A
(zh)
*
|
2017-03-23 |
2017-07-28 |
中国药科大学 |
胃泌酸调节素（oxm）类似物及其应用
|
|
EP3670529B1
(en)
*
|
2017-08-16 |
2024-01-24 |
Dong-A St Co., Ltd. |
Acylated oxyntomodulin peptide analog
|
|
MX2020003217A
(es)
|
2017-09-25 |
2020-07-29 |
Merck Sharp & Dohme |
Coagonistas de accion prolongada de los receptores de glucagon y glp-1.
|
|
CN115109166B
(zh)
*
|
2017-11-24 |
2025-07-18 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多结构域活性蛋白
|
|
CN115304666B
(zh)
*
|
2017-11-24 |
2025-09-19 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的胰高血糖素类似物
|
|
CN111171135B
(zh)
*
|
2018-11-12 |
2023-04-07 |
天津药物研究院有限公司 |
具有双重受体激动作用的胰高血糖素衍生肽及其用途
|
|
JP2022516439A
(ja)
|
2018-12-21 |
2022-02-28 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
二特異性タンパク質
|
|
US11471512B2
(en)
|
2019-03-01 |
2022-10-18 |
Merck Sharp & Dohme Llc |
Pharmaceutical compositions of a peptide
|
|
CN110684082B
(zh)
*
|
2019-10-08 |
2021-12-10 |
江苏诺泰澳赛诺生物制药股份有限公司 |
Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
|
|
EP3842060A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled lactam co-agonists of the glucagon and glp-1 receptors
|
|
EP3842449A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled olefin co-agonists of the glucagon and glp-1 receptors
|
|
EP3842061A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled triazole co-agonists of the glucagon and glp-1 receptors
|
|
KR102154959B1
(ko)
*
|
2020-04-29 |
2020-09-10 |
동아에스티 주식회사 |
지속형 glp-1 및 글루카곤 수용체 이중작용제
|
|
CN113621045A
(zh)
*
|
2020-05-09 |
2021-11-09 |
天津药物研究院有限公司 |
具有双受体激动作用的多肽衍生物及其用途
|
|
CN112898405B
(zh)
*
|
2021-01-22 |
2023-02-28 |
深圳市图微安创科技开发有限公司 |
多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
|
|
WO2022257979A1
(en)
|
2021-06-09 |
2022-12-15 |
The Scripps Research Institute |
Long-acting dual gip/glp-1 peptide conjugates and methods of use
|
|
CN119930789A
(zh)
*
|
2023-11-06 |
2025-05-06 |
成都奥达生物科技有限公司 |
一种gcg激动剂化合物
|